AU2003272068A1 - Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators - Google Patents
Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulatorsInfo
- Publication number
- AU2003272068A1 AU2003272068A1 AU2003272068A AU2003272068A AU2003272068A1 AU 2003272068 A1 AU2003272068 A1 AU 2003272068A1 AU 2003272068 A AU2003272068 A AU 2003272068A AU 2003272068 A AU2003272068 A AU 2003272068A AU 2003272068 A1 AU2003272068 A1 AU 2003272068A1
- Authority
- AU
- Australia
- Prior art keywords
- benzimidazolon
- derivatives
- potassium channel
- cortical neuron
- neuron activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005201685A AU2005201685B2 (en) | 2002-10-21 | 2005-04-21 | Derivatives of N-Phenylanthranilic Acid and 2-Benzimidazolon as Potassium Channel and/or Cortical Neuron Activity Modulators |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41952502P | 2002-10-21 | 2002-10-21 | |
US60/419,525 | 2002-10-21 | ||
PCT/IL2003/000855 WO2004035037A2 (en) | 2002-10-21 | 2003-10-21 | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005201685A Division AU2005201685B2 (en) | 2002-10-21 | 2005-04-21 | Derivatives of N-Phenylanthranilic Acid and 2-Benzimidazolon as Potassium Channel and/or Cortical Neuron Activity Modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003272068A1 true AU2003272068A1 (en) | 2004-05-04 |
AU2003272068A8 AU2003272068A8 (en) | 2004-05-04 |
Family
ID=32108098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003272068A Abandoned AU2003272068A1 (en) | 2002-10-21 | 2003-10-21 | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1553932A2 (en) |
JP (1) | JP2006513154A (en) |
KR (1) | KR20050074493A (en) |
AU (1) | AU2003272068A1 (en) |
CA (1) | CA2503075A1 (en) |
WO (1) | WO2004035037A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
EP2203411B1 (en) | 2007-09-20 | 2016-01-06 | Ramot at Tel-Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
GB0723794D0 (en) | 2007-12-05 | 2008-01-16 | Lectus Therapeutics Ltd | Potassium ion channel modulators and uses thereof |
GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
CA3077659A1 (en) * | 2017-10-09 | 2019-04-18 | Ramot At Tel-Aviv University Ltd. | Modulators of potassium ion and trpv1 channels and uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5032189A (en) * | 1973-07-20 | 1975-03-28 | ||
JPS5095285A (en) * | 1973-12-26 | 1975-07-29 | ||
JPH05132431A (en) * | 1990-03-28 | 1993-05-28 | Nippon Oil & Fats Co Ltd | Polymerized pharmaceutical agent and its preparation |
US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
ITMI962356A1 (en) * | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | USE OF COMPOUNDS DERIVED FROM MOLECULES WITH NON-STEROID ANTI-INFLAMMATORY ACTIVITY FOR THE PREVENTION AND TREATMENT OF |
ATE344791T1 (en) * | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-BROMINE OR 4-IODINE PHENYLAMINO)BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS |
US6291442B1 (en) * | 1998-02-03 | 2001-09-18 | The General Hospital Corporation | Pharmacological modulators of voltage-gated potassium ion channels |
AU760250B2 (en) * | 1998-12-04 | 2003-05-08 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
US6472165B1 (en) * | 1999-08-03 | 2002-10-29 | Arzneimittelwerk Dresden Gmbh | Modulatory binding site in potassium channels for screening and finding new active ingredients |
US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
WO2001078721A1 (en) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | Aβ42 LOWERING AGENTS |
US6429223B1 (en) * | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
GB0026838D0 (en) * | 2000-11-02 | 2000-12-20 | Glaxo Group Ltd | Treatment method |
US6593349B2 (en) * | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
EP2203411B1 (en) * | 2007-09-20 | 2016-01-06 | Ramot at Tel-Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
-
2003
- 2003-10-21 CA CA002503075A patent/CA2503075A1/en not_active Abandoned
- 2003-10-21 EP EP03753909A patent/EP1553932A2/en not_active Withdrawn
- 2003-10-21 WO PCT/IL2003/000855 patent/WO2004035037A2/en active Application Filing
- 2003-10-21 JP JP2004544675A patent/JP2006513154A/en active Pending
- 2003-10-21 KR KR1020057006856A patent/KR20050074493A/en not_active Application Discontinuation
- 2003-10-21 AU AU2003272068A patent/AU2003272068A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006513154A (en) | 2006-04-20 |
CA2503075A1 (en) | 2004-04-29 |
WO2004035037A3 (en) | 2004-06-03 |
KR20050074493A (en) | 2005-07-18 |
AU2003272068A8 (en) | 2004-05-04 |
EP1553932A2 (en) | 2005-07-20 |
WO2004035037A2 (en) | 2004-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003257937A1 (en) | Methods and compositions for treatment of dermal conditions | |
AU2003235403A1 (en) | Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide | |
AU2003295801A1 (en) | MODULATION OF HIF1Alpha AND HIF2Alpha EXPRESSION | |
AU2003217737A1 (en) | Method of analyzing investments using overlapping periods | |
AU2003288902A1 (en) | Microcapsules and methods of use | |
AU2003224607A1 (en) | Absorbent composition and method of assembling | |
AU2002950862A0 (en) | Furanone derivatives and methods of making same | |
AU2003216586A1 (en) | Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases | |
AU2002366103A1 (en) | Modulators of rho c activity | |
AU2003303287A1 (en) | Method of cardiac risk assessment | |
AU2003259717A1 (en) | Modulators of rabggt and methods of use thereof | |
AU2003291700A1 (en) | Oral hygiene system and method of treatment | |
AU2002350254A1 (en) | Novel carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use | |
AU2003222979A1 (en) | Emergency beacon and method of adjusting beacon transmit period | |
AU2003205558A1 (en) | Thioibotenic acid and derivatives thereof | |
AU2003272068A1 (en) | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators | |
AU2003225161A1 (en) | Enhancement of human epidermal melanogenesis | |
AU2003206872A1 (en) | Derivatives of (1-benzyl-piperidine-4-yl)-diphenyl-methanol and their use as pesticide | |
AU2003265914A1 (en) | Shear modification of hdpe-clay nanocomposites | |
AU2002360405A1 (en) | Modulators of rho c activity | |
AU2002356981A1 (en) | Modulators of rho c activity | |
AU2003282593A1 (en) | Polyphenolamine composition and method of use | |
AU2003295790A1 (en) | Modulation of iap-like expression | |
AU2003273362A1 (en) | Scrubber and method of using scrubber | |
AU2002952129A0 (en) | Treatment of hypersensitivity conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |